These studies demonstrate that inhibition of the thioredoxin antioxidant system by the FDA-approved anti-rheumatic agent Au inhibits thioredoxin reductase activity and sensitizes pancreatic cancer cell lines to treatment with P-AscH− in a manner that is dependent on H2O2. Here, PRDX5 is linked to familial pancreatic carcinoma.